Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due to uncertainties tied to an evolving virus and the changing competitive landscape and regulatory landscape for innovative vaccines.
The stellar efficacy and safety profile of Moderna's covid vaccine offered rapid validation of the firm's mRNA technology.
Moderna's Alexion partnership was terminated in 2017 after failure to find a safe but effective dose for the lead program, which could foreshadow difficulty finding a therapeutic window beyond low-dose vaccine programs.
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 9.22 |
Price/Book Value | 11.15 | 1.20 | 1.88 |
Price/Sales | 33.64 | 7.77 | 2.53 |
Price/Cash Flow | — | — | 10.46 |
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Quick Ratio | 2.08 | 7.71 | 0.85 |
Current Ratio | 2.29 | 7.85 | 1.27 |
Interest Coverage | −79.21 | — | 2.36 |
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | −23.64% | −5.73% | 8.46% |
Return on Equity (Normalized) | −33.54% | −6.58% | 19.70% |
Return on Invested Capital (Normalized) | −31.72% | −6.97% | 12.66% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>k&<$s | LOCK|$FYs | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Cl&n>@f | LOCK|RC>? | $76B | |||
| argenx SE ADR
ARGX
| LOCK|!<Q?fL | LOCK|yR | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<cJ&l% | LOCK|#@ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^&C%%^H | LOCK|J^hW% | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|dmjNRmm< | LOCK|Llj>b | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|zfQ>q#$ | LOCK|?YT | $24B | |||
| Incyte Corp
INCY
| LOCK|HX>z#? | LOCK|R! | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&tHcyKT | LOCK|cj | $15B |
United States